BioSpace News Archive

Bota Bio and Medichem announced a commercial development collaboration to increase sustainability while reducing the costs of API manufacturing.

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million.

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA has been approved by the Japan Pharmaceuticals and Medical Devices Agency for the adjuvant treatment for patients with BRCA-mutated, human epidermal growth factor receptor 2 -negative high recurrent risk breast cancer.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology.

Clearside Biomedical, Inc. announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

Innovent Biologics, Inc. announced 2022 interim results and major company updates.

Longeveron Inc. today announced that the European Patent Office (EPO) has issued a notice of its intent to grant the Company a patent (EP Application No. 15861319.0) related to methods to treat endothelial dysfunction.

Frontier Medicines Corporation today announced the appointment of Mark Dizon, J.D., to the position of general counsel.

Anthos Therapeutics oday announced the initiation of recruitment for its second Phase 3 clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa.

South Rampart Pharma announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain 2022 World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.